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ABSTRACT
Polypyrimidine tract binding protein (PTBP1) is a
widely expressed RNA binding protein that acts as
a regulator of alternative splicing and of cytoplasmic
mRNA functions. Vertebrates contain two closely-
related paralogs with >75% amino acid sequence
identity. Early replacement of PTBP1 by PTBP2 dur-
ing neuronal differentiation causes a concerted set
of splicing changes. By comparison, very little is
known about the molecular functions or physiologi-
cal roles of PTBP3, although its expression and con-
servation throughout the vertebrates suggest a role
in haematopoietic cells. To begin to understand its
functions we have characterized the mRNA and pro-
tein isoform repertoire of PTBP3. Combinatorial alter-
native splicing events at the 5′ end of the gene allow
for the generation of eight mRNA and three major
protein isoforms. Individual mRNAs generate up to
three protein isoforms via alternative translation initi-
ation by re-initiation and leaky scanning using down-
stream AUG codons. The N-terminally truncated
PTBP3 isoforms lack nuclear localization signals
and/or most of the RRM1 domain and vary in their
RNA binding properties and nuclear/cytoplasmic
distribution, suggesting that PTBP3 may have major
post-transcriptional cytoplasmic roles. Our findings
set the stage for understanding the non-redundant
physiological roles of PTBP3.
INTRODUCTION
RNA binding proteins are the key players that orchestrate
regulation of gene expression at post-transcriptional levels,
including nuclear pre-mRNA processing, mRNA transport
to the cytoplasm, localization, translation and turnover.
RNA binding proteins are often not dedicated to a single
molecular process but can regulate many of the steps in the
mRNA life-cycle. Consequently, a characteristic feature of
many of these multi-tasking proteins is the ability to shut-
tle between the nucleus and the cytoplasm. Some of these
regulatory proteins are members of close families of par-
alogs, the members of which show a high degree of redun-
dancy in function but, crucially, which also have differential
activity on subsets of transcripts. Cell-type specific switch-
ing between expression of different paralogs can be used
to regulate programs of post-transcriptional gene expres-
sion (reviewed in (1)). A good example of a family of nu-
clear and cytoplasmic multi-tasking proteins is provided by
mammalian Polypyrimidine Tract Binding protein (PTBP1
also known as PTB) and its paralogs PTBP2 (also known
as neuronal or brain PTB: nPTB/brPTB) and PTBP3 (also
known as Regulator of Differentiation 1: ROD1).
PTBP1 was originally identified as a protein that could
bind to the polypyrimidine tract at the 3′ splice site of in-
trons (2,3). It was subsequently shown to be a repressive reg-
ulator of splicing (4,5), although more recent global anal-
yses show that it can both repress or activate splicing de-
pendent on its location of binding (6–9). PTBP1 also reg-
ulates pre-mRNA 3′ end processing and various cytoplas-
mic functions, including mRNA localization, stability and
translation (10,11). Although the steady-state distribution
of PTBP1 in many cells is predominantly nuclear, protein
kinase A phosphorylation of Ser-16, which is embedded
within a bipartite nuclear localization signal (NLS) leads
to a redistribution towards the cytoplasm allowing PTBP1
to regulate cytoplasmic functions (12,13). Much is known
about the role of switching between PTBP1 and PTBP2
expression during neuronal differentiation and maturation
(reviewed in (14)). In non-neuronal cells, PTBP2 expression
is switched off, even if the gene is transcribed, by PTBP1 in-
duced skipping of PTBP2 exon 10, which leads to Nonsense
Mediated Decay (15–17). During neuronal differentiation,
miR124 downregulates PTBP1 expression, which in turn
leads to upregulation of PTBP2 (16). Although the PTBP2
has similar activity to PTBP1 for many events (17), a co-
ordinated set of splicing events are sensitive to the switch
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from PTBP1 to PTBP2 (15). Later in development, PTBP2
expression also decreases and this in turn leads to a second
wave of alternative splicing changes characteristic of adult
brain and essential for brain development (8,18).
While the functions and developmental roles, particularly
in neurons, of PTBP1 and PTBP2 have been well studied
the third mammalian paralog, PTBP3 has been relatively
neglected. Originally identified as Regulator of Differen-
tiation 1 (ROD1 (19)) it has been identified primarily in
haematopoietic cells. By analogywith the key role of PTBP2
in neuronal differentiation, we expect that PTBP3 will have
an important non-redundant role in the hematopoietic sys-
tem. Given the high degree of amino acid identity of PTBP3
with PTBP1 and 2, it is expected to be involved in similar
molecular functions. Splicing repressor activity of PTBP3
has been demonstrated upon a FAS exon 6 splicing re-
porter (20) while analysis of interacting proteins indicated
an unexpected involvement with Nonsense Mediated De-
cay (21). PTBP1 and PTBP2 also cause skipping of exon
2 of PTBP3, but the functional consequences of this event
have been unclear (17). When exon 2 is included, AUG1
(i.e. the first AUG triplet from the 5′ end of the transcript;
see Figure 2 legend for explanation of AUG numbering) in
exon 1 opens a reading frame encoding a 555-amino acid
protein with 76% identity to PTBP1 (Supplementary Fig-
ure S1). Skipping of the 34 nt exon 2 causes a frameshift
and termination of the AUG1 reading frame after only 20
codons. Despite the fact that exon 2 skipped mRNAs have
the upstreamORF (uORF) initiating at AUG1, they are not
substrates for Nonsense Mediated Decay (NMD) (17). The
annotated start codon for transcripts lacking exon 2 (e.g.
ENST00000374257) is AUG4 (19). Indeed, western blot de-
tection of PTBP3 showed proteins of ∼57 and 50 kDa, the
larger of which could correspond to protein initiating at
AUG4 (19). However, the identity of the 50 kDa band is
unclear and no protein of ∼60 kDa, corresponding to initi-
ation at AUG1, was detected.
Given its expected importance in haematopoietic cells, we
set out to characterize the mRNA and protein isoform di-
versity of PTBP3. We show that complex AS at the 5′ end
of PTBP3 results in the generation of 8 distinct mRNA iso-
forms, none of which is NMD sensitive. However, the gener-
ation of uORFs results in individual mRNA isoforms that
generate more than one protein isoform via translation ini-
tiation at downstreamAUGs bymechanisms of re-initiation
and leaky scanning. The resultant PTBP3 protein isoforms
are truncated at the N-terminus, differ in the presence of
the bipartite NLS and number of intact RNA Recognition
Motif (RRM) domains, and in their subcellular localization
and RNA binding. Strikingly, a major protein isoform ini-
tiates at AUG11, truncating RRM1; this major initiation
codon has not been correctly identified in the annotated
Refseq, Ensembl, or Gencode isoforms.
MATERIALS AND METHODS
DNA constructs
All PTBP3 expression constructs used the pEGFP-N1
vector. To study the expression of PTBP3 mRNAs, two
I.M.A.G.E. clones were used for full length PTBP3
(CR749471) and PTBP32 (BC039896). The PTBP34
and PTBP324 ORFs were cloned from cDNAs ex-
tracted from K562 cells. Mutations to study translation ini-
tiation usedAUG toUUGmutations to disrupt recognition
of initiator codons (UUG), tgggccAUGga to gccaccAUGga
mutation to put AUG1 in a perfect Kozak context (cAUG)
and UGA to UGC mutation of the stop codon in the
AUG1 uORF to allow expression from AUG1 (fAUG).
The FAS exon 6 splicing reporter containing the human
genomic sequence from exons 5 to 7, was kindly pro-
vided by K. M. Izquierdo and J. Valcarcel. A codon op-
timized AUG1 PTBP3 ORF sequence for transient ex-
pression in mammalian cells was obtained from GeneArt
and was cloned into HindIII/BamHI sites of the pEGFP-
N1 vector (Clontech). We cloned sequences starting from
AUG4 and AUG11 to force expression from these start
codons. To direct nuclear expression of PTBP3 isoforms,
the SV40NLSPKKKRKVwas cloned into the vectors into
BamHI/AgeI sites. PTB1-GFP and PTB4-GFP expression
vectors were generated in pEGFP-N1. For expression of
C-terminally His-tagged recombinant PTBP3 proteins, the
PTBP3 ORF sequences were cloned into the pET-21d vec-
tor using EcoRI/HindIII sites.
Cell culture and transfections
K562 cells were maintained in 10 cm plates in RPMI
medium with glutamax (Life Technologies) supplemented
with 10% (v/v) Fetal Calf Serum, Biosera (FCS). RNAi
transfections in K562 cells were performed as follows. On
day 1, K562 cells were seeded in spinner flasks at 2 × 105
cells/ml.On day 2, 2× 105 cells were seeded in 24-well plates
in 100l medium. A total of 20 pmol siRNA (5 pmol P1, 10
pmol N1, 5 pmol Rd9 made up with C2) was diluted in 100
l OptiMEM-1 (Gibco, Life technologies), then 6l HiPer-
fect (QIAGEN)was added and themixture incubated for 10
min. This transfection mixture was added to each well, then
after 6 h, 400 l RPMI was added to each well. On day 3,
cells were transferred to a 6-well plate and the siRNA trans-
fection was repeated. After 6 h, 1.5 ml RPMI was added to
each well. Cells were harvested after 72 h. mRNA targets
for gene specific knockdownwere as follows: human PTBP1
P1 (22); human PTBP2 N1 (17), human PTBP3 Rd9, 5′-
UGCCGUUACUAUGGUGAAUUA-3′; and control C2
(23). siRNAs were purchased from Dharmacon. HeLa and
HEK-293T cells were typically maintained in 10 cm plates
in dulbecco’s modified Eagle’s medium (DMEM) with glu-
tamax (Gibco, Life technologies) supplemented with 10%
(v/v) FCS. For splicing reporter assays, 3× 105 HEK-293T
cells were plated in 35mmdiameter wells 24 h prior to trans-
fection in 1.5mlDMEM.A total of 200 ng splicing reporter
and 400 or 800 ng GFP expression vector, made up to a to-
tal of 1 g plasmid with pGEM4Z was transfected using
2 l LipofectAMINE 2000TM reagent (Invitrogen). RNA
and protein were harvested 48 h following transfection. For
fluorescence microscopy experiments, HeLa cells grown on
glass coverslips were transfected with 2 g PTBP3-AUG1,
PTBP3-AUG4, PTBP3-AUG11 pEGFP-N1 constructs us-
ing 4 l LipofectAMINE 2000TM reagent (Invitrogen).
Primary B cell single cell suspensions were prepared from
spleens of C57BL/6 mice by passing the spleen consecu-
tively through a 70 and 40 m nylon mesh. B cells were
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isolated by negative MACS sorting with the mouse B cell
isolation kit from Miltenyi Biotec. B cells were cultured
in IMDM media (Life Technologies) supplemented with
10% FCS (GIBCO), 50 M -mercaptoethanol (Sigma)
penicillin and streptomycin (GIBCO) and stimulated with
10g/ml LPS (127:B0, Sigma) for 48 h.
Fluorescence microscopy
Twenty-four hours after transfection, cells were fixed in for-
malin (SIGMA), permeabilized in 0.5%Triton in phosphate
buffered saline (PBS) for 5min, blocked in 1% bovine serum
albumin (BSA) in PBS, stained with anti-PTBP1 mono-
clonal antibody in PBS (1:200) for 1 h, washed with PBS
and incubated with secondary mouse antibody conjugated
to rhodamine (1:200) (Jackson ImmunoResearch) for 1 h.
All incubations were performed at room temperature in the
absence of light. Coverslips were mounted in Mowoil (Cal-
biochem). Cells were observed under anOlympus BX61mi-
croscope with a 100X/1.30 oil immersion objective.
Protein and RNA analysis
Total protein was harvested with RIPA buffer supple-
mented with protease inhibitors or by direct lysis in sodium
dodecyl sulphate (SDS) loading buffer when total cell
lysates were analysed. For cytoplasmic and nuclear frac-
tions of cell lines 106 cells were resuspend in 50 l ice-
cold buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10
mM KCl, 0.5 mM dithiothreitol (DTT), 0.2 mM phenyl-
methanesulfonylfluoride (PMSF)), incubated on ice for 30
min and lyzed with a pestle. Samples were centrifuged for
1 min at 13 000 r.p.m. Supernatant was collected as cy-
toplasmic fraction, nuclear pellets were resuspended in 50
l of SDS loading buffer. Cytoplasmic and nuclear frac-
tions of mouse B cells were harvested with cytosolic ly-
sis buffer (10mM Tris–HCl, pH 7.4, 10mM NaCl, 2.5 mM
MgCl2, 40 g/ml digitonin and protease inhibitors) and to-
tal lysis buffer (50 mM Tris–HCl, pH 7.4, 100 mM NaCl,
1% NP-40, 0.1% SDS, 0.5% sodium deoxicholate and pro-
tease inhibitors). Equivalent amounts were separated in
12.5% (w/v) sodium dodecylsulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) except gels containing mouse
B cell protein extracts which were separated in NuPAGE
Novex 4–12% Bis-Tris Gels (Life Technologies).
Anti-PTBP1 mouse monoclonal antibody (BB7) was
obtained from D. Black, anti-PTBP1 mouse monoclonal
antibody (Clone 1) from Invitrogen, anti-PTBP2 rabbit
polyclonal antibody from A. Willis, anti-ERK antibody
from Santa Cruz and anti-GFP antibody from Molecular
Probes/Invitrogen. Anti-Lamin A/C (636) and anti-Lamin
A/C (H110) were obtained from Santa Cruz, anti-tubulin
(YL1/2) was obtained from Abcam and anti-GAPDH
(D16H11) was purchased from Cell Signalling.
Three anti-PTBP3 antibodies were used: rabbit poly-
clonal PTBP3-FL antibody, rabbit polyclonal PTBP3-L2–3
and rat anti-PTBP3 monoclonal antibody (MAC454). The
rabbit polyclonal PTBP3-FL antibody was raised in a rab-
bit against PTBP3-AUG4 (Eurogentec) and affinity puri-
fied and depleted of PTBP1 and PTBP2 crossreacting anti-
bodies as previously carried out for anti-PTBP2 (17). Rab-
bit polyclonal PTBP3-L2–3 antibody was raised in a rabbit
(Cambridge Research Biochemicals) against recombinant
GST-mouse Ptbp3 protein containing part the RRM2 to
RMM3 linker (amino acids 279–359) of the AUG1 mouse
Ptbp3 isoform. The antibody was first positively purified
by affinity chromatography with the GST-mouse Ptbp3 re-
combinant protein used in the immunization and subse-
quently depleted of anti-GST and PTBP1 antibodies by
negative affinity chromatography purification using a GST
fusion recombinant protein containing part of the RRM2
toRRM3 linker ofmouse Ptbp1 (278–360 amino acids from
the mouse Ptb4 isoform). The rat monoclonal AbMAC454
will be described in detail elsewhere. The antigen used for
rat immunizations was the GST-mouse Ptbp3 RMM2 to
RRM3 linker recombinant protein used also for the gener-
ation of the rabbit polyclonal PTBP3-linker-2–3 antibody.
Where necessary, western blots were quantitated by densit-
ometry of autoradiographs using Total lab TL120 software
(Nonlinear Dynamics).
RNA was harvested with TRI reagent (Sigma) accord-
ing to the manufacturer’s protocol. Reverse transcription
(RT) reactions were carried out using Superscript II (In-
vitrogen), 1–2 g total RNA and oligo dT. Detection of
PTBP3 transcripts by polymerase chain reaction (PCR) am-
plification used 1/20th of the RT reaction as template and
400 ng PTBP3–1aF primer (5′ TCCATCTGGGCCATG-
GAT 3′) and 160 ng 32P-5′-labelled PTBP3 5R primer (5′
CAGCTTCCTCAGAAGCCATT3′). Reactionswere sepa-
rated by denaturing polyacrylamide gel electrophoresis and
quantitated by phosphorimager. Analysis of the minigene
reporters were carried out as described in (6,20). Analysis of
FAS in vitro splicing was carried out as described in (24,25).
Statistical significance between percent exon inclusion was
assessed by unpaired two-tailed Student’s t-test.
Visualization of K562 and mouse B-cell RNAseq data
Two RNAseq libraries (GSM1289404 and GSM1289405)
from K562 cells (26) were downloaded from the Gene
Expression Omnibus (GEO) repository. Details for RNA
purification, library preparation and sequencing can be
found under theGEOaccession numbers. RNAseq libraries
were trimmed with Trim Galore (version 0.3.7, http://www.
bioinformatics.babraham.ac.uk/projects/trim galore/)
using paired-end trimming mode and default parameters.
Reads were mapped to the human hg19 genome. Mapping
was carried out with TopHat version 2.0.12 (27) using -p
6 -g 1 parameters and the Homo sapiens.GRCh37.61.gtf
annotation. RNAseq libraries from mouse primary B
cells (GSM1520107, GSM1520108, GSM1520109 and
GSM1520110) have been described elsewhere (28). Reads
were trimmed with TrimGalore (v0.3.3, default parame-
ters). Mapping to the mouse mm10 genome was carried
out with TopHat (v2.0.7) using -p 6 -g 1 parameters and
the Mus musculus.GRCm38.70.gtf annotation. Mapped
reads were visualized in Sashimi plots generated with IGV
(29). The minimum junction coverage was set to 30 for
K562 cells and to 5 for mouse B cells when Sashimi plots
were generated.
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Expression and purification of recombinant PTBP3 proteins
His-tagged PTBP3 proteins were expressed in Escherichia
coli BL21 cells. Cells were lysed in 300 mM NaCl, 50 mM
NaH2PO4 buffer (pH 8.0) supplemented with protease in-
hibitor cocktail (Roche) and His-tagged proteins were puri-
fied using Ni-NTA beads (QIAGEN). The purified proteins
were eluted with 300 mM NaCl, 50 mM NaH2PO4 buffer
(pH 8.0), 400 mM imidazole, supplemented with protease
inhibitor cocktail (Roche), then dialyzed against 20 mM
HEPES, pH 7.9, 300 mMKCl, 0.2 mM ethylenediaminete-
traacetic acid, 0.5mMDTT, 20% glycerol. The purified pro-
teins were at least 90% pure, as verified by Coomassie stain-
ing of samples run on SDS-PAGE.
RNA binding assays
RNAs were transcribed with T7 RNA polymerase (pre-
pared in house) from a linearized DNA template incorpo-
rating trace amounts of [32P]UTP. RNAs were phenol ex-
tracted, purified using a G50 Micro Column (ProbeQuant)
and quantified by scintillation counter (Beckman LS 3801).
For UV-crosslinking 5–10 fmol of RNAwas incubated with
400 nM PTBP3 protein and 0.25 g rRNA in 10 mM
HEPES, pH 7.9, 3 mM MgCl2, 5% (v/v) glycerol, 1 mM
DTT, 100 mMKCl at 30◦C for 30 min. Heparin was added
(0.33 mg/ml) 5 min before the end of the reaction. Samples
were exposed to 2 × 960 mJ UVC per cm2 in a crosslinker
(Spectronics) before digestion with RNase T1 (0.8 U/l)
and RNase A (0.28 mg/ml) (Sigma). Crosslinked proteins
were resolved by SDS-PAGE and autoradiography.
For filter binding, 20 l reactions were assembled in 96-
well plates. Reactions contained 4 l 5× binding buffer
(50 mM HEPES, 15 mM MgCl2, 5 mM DTT, 25% (v/v)
glycerol), 2 l 0.5 mg/ml tRNA (Sigma), 0.8 l 33U/l
RiboShieldTM Ribonuclease inhibitor (Dundee Cell Prod-
ucts), 1 l 100 M BSA. To this 4 l recombinant
protein/buffer E and the appropriate dilution of RNA was
added and final KCl adjusted to 100 mM. Reactions were
incubated at 30◦C, 15 min before being added to an as-
sembled Whatman R© Minifold R© I 96 well dot-blot assem-
bly with a Protran NBA-085B Nitrocellulose membrane
(Whatman), and aHybond-N (GEHealthcare). Bothmem-
branes were pre-incubated in wash buffer (10 mM HEPES,
2.5 mM MgCl2, 5% (v/v) glycerol, 1 mM DTT) for 1 h.
Wells were first washed with 200 l wash buffer, bind-
ing reactions were applied followed by 200 l of wash
buffer. Membranes were dried, exposed to a Phosphorim-
ager screen (GE Healthcare) and scanned using a Storm
Phosphorimager (GE Healthcare). Data was analysed us-
ing ImageQuant TL software (GE Healthcare). Dissocia-
tion constants were calculated as: KD = [R][P]/[R.P] where
[R], [P] and [PR] correspond to free RNA, free protein and
bound complex concentrations respectively. All RNA con-
centrations were at least 100-fold lower than the lowest pro-
tein concentration, so total protein could be used as the free
protein concentration. By plotting bound/free RNA ver-
sus the input protein concentration the gradient is equal to
1/KD. Statistical significance between KDs was assessed by
unpaired two-tailed Student’s t-test.
Chymotryptic digestion
Reactions were performed in buffer E with 10 mM CaCl2.
Recombinant protein and chymotrypsin (Sigma) were
added to final concentration of 12.5 ng/l and 0.21 ng/l
respectively. The reaction was incubated at 25◦C and 10 l
fractions removed at set time points were added directly to
10 l 2× SDS loading buffer at 90◦C and incubated at 90◦C
for 2 min. The 0 min time point was removed prior to the
addition of chymotrypsin and added directly to 10 l 2×
SDS loading buffer at 90◦C, after which the chymotrypsin
was added. A negative control sample was generated by re-
moving a fraction prior to the addition of chymotrypsin and
chymotrypsin buffer (1 mM HCl, 2 mM CaCl2) added in-
stead of chymotrypsin. This sample was incubated at 25◦C
for the same length of time at the longest time point. All
fractions were subjected to SDS-PAGE and visualized by
silver staining.
RESULTS
Extensive alternative splicing of PTBP3
In addition to the skipping of PTBP3 exon 2, exon 4 can
be skipped and exon 3 has alternative 5′ splice sites (5′ ss)
separated by 9 nt (Figure 1A). To determine the extent to
which these splicing events occur in haematopoietic cells,
we used primers in exons 1 and 5 to carry out RT-PCR
analysis of transcripts from the human erythroleukaemia
cell line, K562. Expression of 8 mRNA species was detected
representing every combination of the annotated alterna-
tive splicing events (Figure 1B, lane 1). The alternative 5′ ss
choice in exon 3 alters the transcripts by only 9 nt, whereas
inclusion or skipping of exons 2 (34 nt) and/or 4 (170 nt)
shifts and prematurely terminates the reading frame initi-
ating at AUG1 in exon 1. We therefore focused on differ-
ences in splicing of exon 2 and exon 4 (Figure 1B). Full
length PTBP3 mRNA only comprises 10% of spliced tran-
scripts, while transcripts with exon 2 skipped and exon 4
included were the most abundant at 48%. Transcripts with
exon 4 skipped alone or in combination with exon 2 skip-
ping comprised 13 and 29% of total mRNAs respectively.
Analysis of available K562 cell mRNA-Seq datasets agreed
with the RT-PCR data. Reads across exon-exon junctions
show thatmost PTBP3 transcripts exclude exon 2, that there
is roughly two-fold more use of the 3L 5′ ss of exon 3 than
the 3s site, and that exon 4 is ∼80% included (Figure 1C).
Moreover the RNAseq data shows no further major alter-
native splicing events downstream of exon 5. Despite the
complexity of expressed mRNA isoforms, we detected only
two major protein isoforms of ∼48 and 57 kDa (Figure 1E,
lane 4), similar to earlier reports (19).
To examine the extent of crossregulation of PTBP3 splic-
ing, we looked for changes in splicing upon PTBP1/PTBP2
knockdown (Figure 1B, D and E). Upon knockdown of
PTBP1, we observed upregulation of PTBP2 (Figure 1E,
lanes 4,5), demonstrating that the PTBP1 crossregulation
of PTBP2 also occurs in K562 cells. Indeed, analysis of
PTBP2RNA showed an increase in exon 10 inclusion from
30 to 90% upon PTBP1 knockdown (Supplementary Fig-
ure S2). Upon combined PTBP1/PTBP2 knockdown, in-
clusion of PTBP3 exon 2 increased from 23 to 84%. In con-
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Figure 1. Combinatorial alternative splicing of PTBP3. (A) Schematic of exon structure and alternative splicing events at 5′ end of PTBP3. Arrows indicate
location of PCR primers used in (B). (B) RT-PCR of PTBP3 mRNA in K562 cells using PCR primers in exons 1 and 5 after treatment with control siRNA
(lane 1) or PTBP1/PTBP2 siRNA (lane 2). Cartoon schematics to the right indicate the identity of the 8 bands. 3s and 3L denote the use of the upstream
and downstream alternative 5′ ss of exon 3. The histogram to the right indicates the proportions of mRNA isoforms with exon 2 and/or exon 4 skipped.
(C) Sashimi plots showing RNAseq data of K562 cells. Data from two RNAseq libraries are shown. Numbers above arcs indicate the number of reads
found that map to a particular exon–exon junction. (D) Quantitation of data from (B) to indicate the percentage inclusion of exon 2, exon 4 and the 3L 5′
ss. Only exon 2 inclusion is sensitive to PTBP1/PTBP2 knockdown. (E) Effects of siRNAs targeting PTBP1, 2 and 3, labelled here above lanes as P1, P2
and P3 respectively. Western blots used the antibodies indicated to the right; -PTBP1 (BB7) and -PTBP3-FL. Lanes, 3, 2, 1: two-fold dilutions of the
control siRNA treated sample in lane 4.
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trast, splicing of exon 4 and use of the downstream 5′ ss in
exon 3 did not change significantly, remaining around 60
and 64% respectively (Figure 1B and D). Therefore PTBP1
and PTBP2 regulate splicing of exon 2, but not the other
splicing events in PTBP3. Western blot analysis showed the
appearance of a larger PTBP3 protein isoform of ∼60 kDa
upon PTBP1/PTBP2 knockdown (Figure 1E, lanes 5,8).
This band, which was undetectable under control condi-
tions (lane 4) represented∼1% of total PTBP3 upon PTBP1
knockdown (lane 5) and 16% upon PTBP1/PTBP2 knock-
down (lane 8). Knockdown of PTBP3 alone or in combina-
tion with PTBP1 and/or PTBP2 confirmed that the 48, 57
and 60 kDa isoforms are PTBP3 (Figure 1E, lanes 6, 7, 9).
The size of the 60 kDa isoform is consistent with translation
of the exon 2 included PTBP3 mRNA using AUG1 as the
initiating codon. Knockdown of PTBP3 had no effect upon
expression of either PTBP1 or PTBP2 (Figure 1E lanes 6,
7; note that the apparent increase in PTBP1 levels in lane 6
was not observed in other experiments).
Skipping of exon 2 (34 nt) and/or exon 4 (170 nt) results
in frameshift and introduction of a premature termination
codon in the reading frame initiating at AUG1. However,
exon 2 and exon 4 skipped transcripts were not stabilized
uponUPF1 knockdown indicating that they are not NMD-
sensitive (Supplementary Figure S3), in contrast to the reg-
ulated splicing events in PTBP1 and PTBP2 (15–17,22).
PTBP3 protein isoforms arise from initiation at alternative
AUGs
The preceding results raise questions about the relationship
between the observed PTBP3 mRNA and protein isoforms,
as well as the nature of the crossregulatory network be-
tween PTBP1, PTBP2 and PTBP3. The predicted transla-
tion products from the differentially spliced PTBP3 mRNA
transcripts are shown inFigure 2.ORFs that can potentially
produce PTBP3 proteins are shown in black and uORFs in
grey. Only the longest mRNA isoform containing exon 2
and 4 has a PTBP3 encoding ORF commencing at AUG1
in exon 1. For all other isoforms, AUG1 initiates a uORF
and potential PTBP3 encoding ORFs initiate at AUGs 4,
10, 11 and 12. Note that the AUGs are numbered according
to their location in the longest mRNA isoform, although
AUGs 6–10 are in exon 4 and so are missing in exon 4
skipped mRNA isoforms. AUG1 is in a good Kozak con-
sensus (Table 1), is present in all mRNA isoforms andwould
be expected to be recognized by a scanning 43S initiation
complex. Initiation at the downstream AUGs could occur
by leaky scanning or translational re-initiation (30,31). Al-
ternative 5′ ss choice at exon 3, alters the coding sequence
by 9 nt, preserving the reading frame and inserting a GVY
tripeptide into PTBP3 isoforms initiating at AUG1 or 4.
However, when exon 4 is skipped, AUG5, which lies be-
tween the two 5′ ss of exon 3, could potentially initiate a
PTBP3 encoding ORF (Figure 2C and D). To ensure that
we examined all possibilities of AUG usage, our subsequent
expression constructs were all based on use of the down-
stream 5′ ss in exon 3.
To determine which proteins are expressed from the dif-
ferent PTBP3 transcripts, their cDNAs were cloned into
mammalian expression vectors to express PTBP3-GFP fu-
sion proteins. A total of four protein isoforms were detected
(Figure 3A). The difference in size suggests that the three
major isoforms correspond to the 48, 57 and 60 kDa iso-
forms observed in K562 and HeLa cells (Figure 1F and
Supplementary Figure S4). To address whether these pro-
tein isoforms arise via alternative translation initiation we
tested the effects of mutating the different potential initiat-
ing AUG codons.
The major protein produced by the full length PTBP3
construct had a size consistent with initiation at AUG1,
with a minor product corresponding to initiation at AUG4
(Figure 3A, lane 1). Consistent with this,mutation ofAUG1
to UUG1 resulted in complete loss of the larger band and
exclusive production of a protein corresponding in size
to the previously minor species (Figure 3B). These ob-
servations agree with the predictions that full length 60
kDa PTBP3 protein is produced from AUG1 in the full
lengthmRNA (Figure 3A). Interestingly, the exon 2 skipped
construct produced three PTBP3 proteins, the smallest of
which was the major product (Figure 3A, lane 2, 3C, lane
1, PTBP32). A series of AUG to UUG mutations pin-
pointed the initiation codons associated with each of the
three proteins (Figure 3C). The UUG4 mutation abolished
the largest band and led to increased amounts of both
smaller bands (Figure 3C, lane 2). This indicates that the
largest band arises from initiation at AUG4, consistent with
its comigration with the minor AUG4 product from FL
PTBP3 (Figure 3A, lanes 1,2). The minor, intermediate
sized band was abolished by the UUG10 mutation (Fig-
ure 3C lane 3) while the most abundant and most rapidly
migrating band was abolished by the UUG11 mutation
(Figure 3C lane 4). Concomitant with disappearance of
the AUG11 band, a new slightly smaller band appeared
in the UUG11 mutant. This was shown to arise from ini-
tiation at AUG12 by a double UUG11/UUG12 mutant
in which both the AUG11 and AUG12 bands disappeared
(Figure 3C lane 6). In contrast, the UUG12 mutation alone
had no effect (Figure 3C, lane 5). These data demonstrate
that the most abundant PTBP3 mRNA isoform in K562
cells (PTBP32) is able to produce the two major 57 and
∼48 kDa isoforms, as well as a third minor isoform. The
only protein isoform that it is unable to generate is the 60
kDa protein initiating at AUG1. Moreover, these data con-
firm that the PTBP3 isoforms arise from translation initia-
tion at alternative AUGs rather than from protein cleavage.
Further mutations were used to examine the possible
translation initiation mechanism in the exon 2 skipped
construct. Strikingly, AUG1 to UUG1 mutation in the
PTBP32 construct abolished the AUG10 and AUG11
proteins, with the major product now initiating at AUG4
(Figure 3D lanes 1,2, Figure 2B). In contrast placing AUG1
in a perfect Kozak consensus (cAUG1, ugggccAUGga to
gccaccAUGga) eliminated expression of the AUG4 isoform
while leaving expression of the AUG11 isoform intact (Fig-
ures 3D, lane 3 and 2B). Taken together the data in Fig-
ure 3D indicates that theAUG10 and 11 products arise from
re-initiation after translation of the AUG1 uORF while
the AUG4 isoform arises from leaky scanning past AUG1
(summarized in Figure 2A).
The exon 4 skipped isoform showed very low levels of ex-
pression, with exclusive production of the AUG11 protein
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Figure 2. Summary of translation initiation from PTBP3 isoforms. Each panel schematically shows one of the four main PTBP3 mRNA isoforms (all with
3L) above, with potential open reading frames (ORFs) below. (A) PTBP3 FL mRNA, with the schematic domain organization of the encoded protein
above (B) PTBP3 2 with exon 2 skipped, (C) PTBP3 4 with exon 4 skipped, (D) PTBP3 24 with exons 2 and 4 skipped. Black bars represent ORFs
that encode full length PTBP3 isoforms. Grey bars represent uORFs. AUG codons are numbered and indicated according to their relative location from
the 5′ end of the full length PTBP3 isoform. Note that the numbering of AUGs refers to the full length isoform, even though AUGs 6–10 lie within exon 4
and are missing from the exon 4 skipped isoforms. The annotations to the right and scores (+, ++ and +++) indicate the relative levels of translation from
each AUG and inferred mechanism from data in Figure 3. Connectors between uORFs and main ORFs imply translational reinitiation.
Table 1. Kozak sequence contexts of PTBP3 AUGs 1–12, classed as strong moderate or weak on the basis of the −3 (A > G) and +4 (G) positions
AUG Translation context Strength
Consensus gcc[a>g]ccAUGgau consensus
AUG1 ugggccAUGgau strong
AUG2 ccauggAUGgug moderate
AUG3 gaucugAUGagc weak
AUG4 uuuaccAUGaau strong
AUG5 guguguAUGgcu moderate
AUG6 cag/augcuaAUGgga moderate
AUG7 augggaAUGaca moderate
AUG8 aauuccAUGuga weak
AUG9 caugugAUGuca moderate
AUG10 cuuuucAUGuug weak
AUG11 uuagaaAUGgcu strong
AUG12 guuacuAUGgug strong
isoform (Figure 3A, PTBP34). The long AUG1 uORF in
PTBP34 overlaps with AUG11 (Figure 2C), excluding the
possibility of re-initiation after the AUG1 uORF (31). Mu-
tation of AUG1 to a perfect Kozak consensus eliminated
AUG11 expression, consistent with a leaky scanning mech-
anism to locate AUG11 in PTBP34 (Figure 3E, lane 2). In
contrast, the double exon 2, exon 4 skipped PTBP324
construct showed efficient and almost exclusive expression
of the AUG11 protein (Figure 3A, lane 4). The combined
skipping of exon 2 and exon 4 puts AUG1 in the same
reading frame with the remainder of PTBP3. Consistent
with the idea that AUG11 use results from reinitiation af-
ter the AUG1 uORF, mutation of the stop codon of the
AUG1 uORF allowed expression exclusively of PTBP3 pro-
tein from AUG1 (Figure 3F, fAUG1). This was confirmed
by a double mutations in the start and stop codons of the
AUG1 uORF, which produced exclusively the AUG11 iso-
form (Figure 3F, fUUG1).
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Figure 3. Translation initiation by PTBP3 proteins. Plasmids encoding PTBP3 fused to GFP at the C-terminal end were transfected into HEK293 cells
and expression detected by western blot with anti-GFP antibodies (upper panels) and anti-ERK as a loading control (lower panels). UUG4, UUG10 etc.
denotes AUG to UUGmutations at the indicated AUG. cAUG1 denotes a mutant creating a Kozak consensus around AUG1. fAUG1/fUUG1 denotes a
UGA to UGC mutation in the stop codon that usually terminates the AUG1 uORF. (A) Wild-type PTBP3 isoforms. (B) Lane 1, WT FL PTBP3 and lane
2, AUG1/UUG1 mutant. (C) PTBP3 2 mRNAs. Lane 1, WT. Lanes 2–6 AUG to UUGmutants. (D) PTBP3 2 mRNAs. Lane 1, WT, Lane 2, UUG1,
Lane 3, Kozak consensus AUG1. (E) PTBP3 4. Lane 1, WT, lane 2, Kozak consensus AUG1. (F) PTBP3 24. Lane 1, WT; lane 2, mutation of stop
codon of AUG1 uORF; lane 3, AUG1 to UUG1 combined with mutation of stop codon of AUG1 uORF.
Taken together, the data of Figure 3 show that the ma-
jor PTBP3 isoforms in K562 cells arise from translation of
mRNAs with exon 2 skipping, with initiation at AUG4 and
11, and minor amounts of an AUG10 isoform. Only the FL
mRNA isoform with exons 2 and 4 included gives rise to
a 60 kDa PTBP3 protein initiating at AUG1. The use of
these AUGs and no others is consistent with their Kozak
sequence contexts (Table 1). The mutational analysis here
indicates that re-initiation and leaky scanning are the ma-
jormechanisms that allow expression of the smaller AUG11
and AUG4 PTBP3 isoforms in the exon 2 and 4 skipped
mRNAs.
Having characterized the nature of the PTBP3 isoforms,
we were next interested in the possible functional differ-
ences. The AUG1 isoform aligns well throughout its length
with PTBP1 and PTBP2 (Supplementary Figure S1), while
initiation at AUG4 and 11 causes N-terminal truncations
that might be expected to alter some functions (Figure 2A).
The AUG4 isoform lacks 31 N-terminal residues including
part of the bipartite NLS (K14R15) (32,33), as well serine-
17, which in PTBP1 is phosphorylated by protein kinase
A shifting localization to the cytoplasm (12). Initiation at
AUG11 has evenmore dramatic consequences, deleting 103
N-terminal amino acids including the entire N-terminal
leader and most of RRM1. Only  helix 2 and  strand 4 of
RRM1 remain, so this isoform might be expected to show
differences in RNA binding as well as localization.
RNA binding by PTBP3 isoforms
To investigate possible differences in RNA binding of the
PTBP3 isoforms we prepared recombinant proteins by ex-
pression in E. coli. RNA binding by all three PTBP3 iso-
forms was readily detected by UV-crosslinking to a probe
from MTDH exon 7 (Figure 4A, lanes 1, 11, 12, 22, 23,
33)(6). The intensity of UV cross-linking by the AUG11 iso-
form was greater than that of AUG1 and 4. However, this
could be related to differential efficiency of photochemistry
rather than real differences in binding. To obtain a semi-
quantitative comparison of binding by the three PTBP3
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Figure 4. RNA binding and chymoytryptic sensitivity of PTBP3 isoforms. (A) PTBP3 proteins were incubated with radiolabelled MTDH exon 7 RNA
probe. Total PTBP3 protein concentration was 400 nM. Lanes 1, 12: AUG1. Lanes 11, 23: AUG4. Lanes 22, 33: AUG11. Lanes 1–11, 12–22 and 23–34
show cross-tirations of AUG1 versus AUG4, AUG1 versus AUG11 and AUG4 versus AUG11. Nanomolar ratios are: 400:0, 380:20, 350:50, 300:100,
250:150, 200:200, 150:250, 100:300, 50:350, 20:380, 0:400. The graphs below show the percentage maximal crosslinking for each individual protein. The
vertical dashed line indicates the equimolar 200:200 ratio, which should be the crossover point if the two isoforms bind with identical affinity. (B) Limited
chymotrypsin digestion of PTBP3 AUG4 (lanes 1–8) and AUG11 (lanes 9–16). Band labelled ‘A’ corresponds to cleavage at Y42/F51 in the N-terminal
leader. Band ‘B’ corresponds to cleavage within the part of RRM1 remaining in AUG11 at Y116, Y117, Y130 or Y133. Bands bracketed as ‘C’ correspond
to multiple cleavages in the linker between RRMs 2 and 3.
isoforms, we carried out competitive UV-crosslinking with
cross-titrations of each pairwise combination of PTBP3
isoforms, maintaining a constant total concentration of
PTBP3 (Figure 4A). The relative crosslinking signal was
normalized to the maximum signal for each isoform, to ac-
count for any isoform-specific variation in crosslinking ef-
ficiency. At the midpoint of the cross-titration the concen-
tration of each isoform is equal (dotted line). Therefore if
the crosslinking signal favours one of the isoforms then that
protein has higher affinity for the RNA. The most strik-
ing observation was that the AUG11 isoform, which lacks
most of RRM1, showed no deficiency in crosslinking. In-
deed AUG11 crosslinked with higher efficiency than AUG4
and with equal efficiency to the AUG1 isoform.
To compare binding affinities directly we used filter bind-
ing assays with a range of RNA substrates including un-
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structured (MTDH exon 7 and [CUCUCU]4) and struc-
tured PTB-binding RNAs (Poliovirus IRES and EMCV
IRES). For these assays we directly compared PTBP3
AUG4 and AUG11 isoforms; we were unable to obtain suf-
ficient quantities of purifiedAUG1 protein for the full range
of comparisons. We also tested an artificial PTBP3 dele-
tion mutant completely lacking RRM1. In agreement with
the UV competition cross-linking (Figure 4A), the AUG11
isoform had a significantly lower KD than AUG4 for bind-
ing to MTDH exon 7 and to PV IRES (Table 2). For the
other two RNAs the dissociation constants for the two iso-
forms were not significantly different. In comparison with
the RRM1 protein, AUG11 had significantly lower KD
for binding to MTDH exon 7 and [CUCUCU]4, suggesting
that the residual part of RRM1 plays a role in RNA bind-
ing. The affinities of the RRM1 and AUG11 proteins for
the PV IRES were similar, and both had significantly lower
KDs than AUG4. Therefore, for some RNAs, as exempli-
fied by PV IRES, a partial or complete lack of RRM1 leads
to higher affinity binding. In contrast, for MTDH exon 7,
the AUG11 isoform binds with higher affinity than either
AUG4 (with intact RRM1) or RRM1.
The higher affinity of AUG11 for some RNAs compared
to either AUG4 or RRM1, suggested that the residual
part of RRM1 might be able to fold in some way so as
to promote RNA binding. As an initial step to probe the
structure of the AUG11 protein we carried out limited chy-
motryptic digestion (Figure 4B). Chymotrypsin cleaves ad-
jacent to the aromatic side-chains of tryptophan, pheny-
lalanine and tyrosine. In natively folded globular domains,
most of these residues are buried and inaccessible. How-
ever, residues in unstructured regions will be accessible for
recognition by chymotrypsin. Consistent with this expecta-
tion limited treatment of PTBP3 AUG4 with chymotrypsin
led to preferential cleavage in the N-terminal leader se-
quence (Y42/F51, bandA) and in the linker betweenRRMs
2 and 3 (F298, Y308, F314, F320, bands C, Figure 4B,
lanes 1–8). There was no evidence of cleavage within any
of the RRM domains. The AUG 11 isoform also showed
the cleavages between RRMs 2 and 3 (bands ‘C’, lanes 9–
16). However, AUG11 was also cleaved at positions cor-
responding to Y116, Y117, Y130 and Y133 in the resid-
ual part of RRM1 (Figure 4B lanes 9–16, band ‘B’). These
residues were not accessible in AUG4, where RRM1 is in-
tact, as shown by the lack of band B in lanes 1–7. These
data suggest that the residual part of RRM1 in the AUG11
isoform does not adopt a stable fold in which the tyro-
sine residues are inaccessible to chymotrypsin. We consid-
ered the possibility that AUG11 might undergo a confor-
mational change upon RNA binding. However, addition of
excess [CUCUU]8 RNA had no effect upon the chymotryp-
tic sensitivity of AUG11 (Supplementary Figure S5).
Localization and splicing activity of PTBP3 protein isoforms
The AUG4 and AUG11 PTBP3 isoforms both lack the
first half of the bipartite NLS (Figure 2A, Supplementary
Figure S1). To test whether this affects their localization
we used fluorescence microscopy of HeLa cells transfected
with expression constructs for GFP-fusions of the PTBP3
isoforms (Figure 5A, GFP) and compared this to endoge-
nous PTBP1 by immunofluorescence (Figure 5A, PTBP1).
Full length PTBP3-AUG1 was predominantly nuclear, sim-
ilar to endogenous PTBP1. However, both PTBP3-AUG4
and PTBP3-AUG11 showed substantial accumulation in
the cytoplasm as well as the nucleus (Figure 5A, middle
and lower rows). Western blots of nuclear and cytoplasmic
fractions also showed that full length PTBP3-AUG1 was
predominantly nuclear, while PTBP3-AUG4 and PTBP3-
AUG11 showed an even nuclear and cytoplasmic distri-
bution (Figure 5B). The difference in localization between
the isoforms is most likely due to the lack of a com-
plete NLS in the AUG4 and 11 isoforms. We next anal-
ysed the nuclear/cytoplasmic distribution of PTBP1 and
PTBP3 in K562 cells by western blot (Figure 5C). While
PTBP1 showed the expected predominant nuclear local-
ization, both the AUG4 and AUG11 isoforms of PTBP3
showed a more even distribution between nuclear and cy-
toplasmic fractions. Thus, the PTBP3 AUG4 and AUG11
isoforms endogenous to K562 cells show a similar cellular
distribution to the transfected constructs in HeLa cells. To
analyse the localization of PTBP3 and PTBP1 in a more
physiological context, we turned to mouse B-cells (Fig-
ure 5D-F). Western blots indicated that B cells contained
higher overall levels of PTBP3 than K562 cells (2.4–2.7-
fold higher, normalized toGAPDH, Figure 5D).Moreover,
while the AUG1 isoform was undetectable in K562 cells, it
represented 24% of PTBP3 in B-cells (Figure 5D). Consis-
tent with this, mRNA-Seq data showed that levels of both
exon 2 and exon 4 inclusion are higher in B-cells than K562
(SupplementaryFigure S6). In contrast, the levels of PTBP1
in B-cells were 70% of the levels in K562 (normalized to
GAPDH). Immunofluorescence analysis of mouse B-cells
indicated that PTBP1 was restricted to the nuclei of mouse
B-cells, but PTBP3 was observed in both the nucleus and
cytoplasm (Figure 5E). Examination of nuclear and cyto-
plasmic enriched fractions from mouse B-cells by western
blots (Figure 5F) also indicated that a higher proportion of
cytoplasmic PTBP3 than PTBP1. Moreover, the full length
AUG1 isoform represented 36% of nuclear PTBP3, but 24%
of the cytoplasmic fraction.
We next compared the activities of the PTBP3-AUG1, -
AUG4 and -AUG11 isoforms and the PTB1 and PTB4 iso-
forms of PTBP1, upon splicing of FAS exon 6 (Figure 6A)
(20,24). Since it has been previously shown that the sub-
optimal codon content of PTBP3 limits expression in our
assays, similar to PTBP2 (20), the GFP-PTBP3 constructs
contained a codon optimized sequence for efficient mam-
malian expression. As a result, all the proteins were ex-
pressed to similar levels (Figure 6B). When transfected into
HEK-293T cells the FAS reporter RNA produces ∼50%
exon 6 inclusion (Figure 6C, lane 1). All of the PTBP1 and
PTBP3 isoforms showed splicing repressor activity, increas-
ing exon 6 skipping. However, the PTBP3-AUG11 isoform
was slightly weaker than theAUG1orAUG4 isoforms (Fig-
ure 6C, lanes 4–6). The lower activity of theAUG11 isoform
could be due to reduced nuclear localization. Tagging the
PTBP3 isoforms with an additional NLS to direct nuclear
localization removed the differences in activity (Figure 6C,
compare lanes 4–6 and 8–10), suggesting that in this assay
the lower activity of the AUG11 isoform is primarily associ-
ated with its localization. The PTBP1 and PTBP3 isoforms
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Table 2. Dissociation constants for binding of PTBP3 proteins to different RNAs
A
RNA AUG4 AUG11 RRM1
MTDH exon 7 91.5 ± 6.6 nM 63.2 ± 3.8 nM 91.1 ± 4.7 nM
[CUCUCU]4 34.8 ± 7.8 nM 43.7 ± 4.8 nM 75.8 ± 11.9 nM
PV IRES 44.1 ± 2.0 nM 23.4 ± 5.5 nM 23.6 ± 4.7 nM
EMCV IRES 6.4 ± 1.3 nM 4.3 ± 0.6 nM 6.5 ± 1.1 nM
B
RNA AUG4 versus AUG11 AUG11 versus RRM1 AUG4 versus RRM1
MTDH exon 7 0.003 0.001 0.932
[CUCUCU]4 0.169 0.012 0.008
PV IRES 0.004 0.955 0.002
EMCV IRES 0.083 0.051 0.965
A; Average Kd ± standard deviation. B; Statistical significance of difference in binding between pairs of PTBP3 proteins. P-values calculated using a
Student’s t-test.
showed a very similar trend in activity for the regulation
of MTDH exon 7 (Supplementary Figure S7). To directly
compare the splicing repressor activity of the PTBP3 iso-
forms with PTBP1 we carried out in vitro splicing of a FAS
exon 5–6–7 construct in HeLa nuclear extract (Figure 6D)
(24,25). Recombinant PTBP1 and PTBP3 isoforms were ex-
pressed and purified fromE coli.FAS exon 6was included to
∼60% in nuclear extract (Figure 6D, lane 1) but the level of
exon skipping increased to∼100% upon addition of PTBP1
(Figure 6D, lanes 2–5). The PTBP3 AUG4 and AUG11 iso-
forms showed identical repressor activity (lanes 6–13, P >
0.37 for all comparisons at the same concentration). We
also tested an artificial PTBP3mutant that completely lacks
RRM1. This protein also had identical activity to the natu-
ral PTBP3 isoforms, showing that RRM1 is dispensable for
regulation of FAS splicing. Taken together, these data sug-
gest that the PTBP3 isoforms have inherently similar splic-
ing activity upon FAS exon 6, but that their activity can be
modulated by their nuclear/cytoplasmic distribution.
DISCUSSION
Our data clarify the identity of the major PTBP3 pro-
tein isoforms and how they are generated by the variety
of mRNA isoforms. The original report of PTBP3 (then
named ROD1) identified the AUG4 isoform as the likely
protein product of an mRNAwith exon 2 skipped but exon
4 included, and noted that the N-terminus was truncated
compared to PTBP1 (19). How AUG4 would be selected
for translation initiation, despite the presence of AUG1 in a
goodKozak consensus context, was not addressed.Western
blots also identified a protein of 50 kDa, but its nature was
unclear. Our data show that the 50 kDa protein arises from
translation initiation at AUG11 to yield a protein with a
truncated RRM1. Notably, although this is the most abun-
dant PTBP3 isoform in K562 and HeLa cells (Figures 1E
and 5D, Supplementary Figure S4) AUG11 has not been
annotated as a start codon in any REFSEQ or ENSEMBL
isoforms. We also show that a full length PTBP3 protein,
corresponding throughout its length to isoform 4 of PTBP1
(Supplementary Figure S1) is the sole translational product
of full length PTBP3mRNA containing exons 2 and 4. This
protein is not usually evident in cultured cells such as K562
or HeLa due to the repressive influence of PTBP1 upon
PTBP3 exon 2 (Figure 1, Supplementary Figure S2)(17).
However, in mouse B-cells, where PTBP1 levels were lower,
the AUG1 PTBP3 was readily detectable (Figure 5). All of
the PTBP3 mRNA isoforms contain AUG1 in exon 1. Se-
lection of the AUG4 and AUG11 initiation codons there-
fore occurs by a mixture of mechanisms other than conven-
tional cap-dependent scanning. Leaky scanning to allowuse
of AUG4 in FL and 2 PTBP3 and of AUG11 in the 4
PTBP3 mRNAs was demonstrated by suppression of these
products when the AUG1 consensus was improved to a per-
fect Kozak context. Most of the AUG11 product is pro-
duced via reinitiation after translation of uORFs initiating
at AUG1 as indicated by the deleterious effects of mutating
AUG1. The influences of uORFs as regulators of gene ex-
pression (34) and of the short peptides encoded by them (35)
are increasingly appreciated. The relative importance of the
non-conventionalmechanisms for translation ofAUG4 and
11 PTBP3 isoforms for quantitative regulation of transla-
tion, compared to the intrinsic functional differences of the
PTBP3 protein isoforms remains to be established.
We examined potential functional differences between
the three PTBP3 isoforms, including RNA binding (Fig-
ure 4), localization (Figure 5) and splicing regulation ofFAS
exon 6 (Figure 6). The clearest observed difference was in
the higher degree of cytoplasmic localization of AUG4 and
11 compared with AUG1 (Figure 5), consistent with trun-
cation of the NLS (Supplementary Figure S1). Surprisingly,
the truncation of RRM1 in the AUG11 PTBP3 did not im-
pair binding to several RNA substrates and was actually
associated with higher affinity binding to some RNAs (Fig-
ure 4A, Table 2), and unimpaired splicing regulatory activ-
ity (Figure 6, Supplementary Figure S7). The lack of effect
on regulation of FAS exon 6 splicing was surprising given
that point mutations that impaired RNA contact by RRM1
of PTBP1 led to a ∼50% loss of activity (25). The relatively
mild consequences of RRM1 truncation in PTBP3 AUG11
contrast with the severely impaired RNA binding and dom-
inant negative function of an isoform of RbFox2 with a
truncation of its single RRM domain (36).
A clearer view of the functional differences between
PTBP3 isoforms requires better knowledge of the cellu-
lar functions and molecular targets of PTBP3. Our anal-
yses were based on the expectation, informed by the high
level of sequence identity (Supplementary Figure S1) that
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Figure 5. Localization of PTBP3 isoforms. Plasmids encoding PTBP3-GFP isoforms initiating at AUG1, 4 or 11 were transfected into HeLa cells and
analysed by (A) fluorescence microscopy, or (B) by cellular fractionation and western blot. (A) Cells were imaged for GFP fluorescence, left column and by
immunofluorescence with PTBP1 antibodies (BB7, middle column). Merged images are shown in the right column. (B) Western blots of cytoplasmic ‘C’
and nuclear ‘N’ fractions from cells transfected with the PTBP3AUG1, 4 and 11GFP fusions. Lamin A/C (626 antibody) is a nuclear marker, while -actin
is cytoplasmic. (C) Western blot of nuclear ‘N’ and cytoplasmic ‘C’ fractions from K562 cells, with Lamin A/C and Tubulin as nuclear and cytoplasmic
markers. Antibodies used were -PTBP1 (BB7) and -PTBP3-FL. A titration of recombinant PTBP1 and PTBP3 (AUG4 isoform) was run on the same gel
to allow estimation of levels of PTBP1 and PTBP3. (D) Western blots of total protein extracts derived from K562 and mouse B cells (duplicate samples).
PTBP3 was detected with the -PTBP3 MAC454 antibody and PTBP1 with Clone 1 monoclonal antibody. GAPDH is show as loading control. (E)
Immunofluorescence microscopy of mouse primary B cells activated with LPS for 48 h. Ptbp3 and Ptbp1 (in white) were detected with -PTBP3-L2–3
polyclonal and -PTBP1 (Clone 1) monoclonal antibodies, respectively. Stainings of pictures at the bottom were carried out with the respective isotype-
matched negative control antibodies. DNA staining (in blue) shows the nucleus. (F) Western blots of cytoplasmic (C) and nuclear (N) fractions from LPS
(48 h) activated mouse B cells. PTBP1 and PTBP3 were detected as in D. Lamin A/C (H110 antibody) is a nuclear marker, while GAPDH is cytoplasmic.
PTBP3 will play similar roles to PTBP1 in regulation of
splicing in the nucleus. The greater cytoplasmic accumula-
tion of the AUG4 and AUG11 PTBP3 isoforms (Figure 5)
suggest that it might have even more prominent cytoplas-
mic roles in mRNA stability and translation than PTBP1
(10). Moreover, by analogy with the unique non-redundant
roles of PTBP2 in neurons (8,14,18), we expect that PTBP3
will also have unique specialized roles, presumably in cells
of the haematopoietic system. In an initial screen for en-
dogenous PTBP3 targets in K562 cells, we tested the re-
sponse of 17 known PTBP1 targets (6) to knockdown of
PTBP3, alone or in combination with PTBP1 and PTBP2
(Supplementary Figure S8, Supplementary Table S1). Only
three events responded to PTBP3 knockdown, including
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Figure 6. PTBP3 isoforms act as repressors of FAS exon 6. (A) Schematic of FAS minigene constructs used for transfection (panels B and C) and in vitro
splicing (panel D). (B) Western blot of HEK239T cells transfected with the indicated GFP fusion proteins. Top panel: anti-GFP. Lower panel: anti-ERK.
(C) RT-PCR analysis of FAS minigene splicing using primers in exon 5 and 7. The histogram below shows the percentage exon 6 inclusion (mean ± s.d.,
n = 3). D) In vitro splicing in HeLa nuclear extract of FAS RNA, with detection of products by primer extension. Lanes 2–5, 6–9, 10–13, 14–17, contain
titrations (75, 150, 300 and 900 nM) of the indicated recombinant proteins: PTB1 isoform of PTBP1 (lanes 2–5), PTBP3AUG4 (lanes 6–9), PTBP3AUG11
(lanes 10–13), PTBP3 RRM1 mutant (lanes 14–17). The histogram below shows the percentage of exon 6 spliced in (mean ± s.d., n = 3). All protein
concentrations above 75 nM produced significantly increased exon skipping compared to nuclear extract alone (P < 0.01, Students two-tailed t-test).
MTDH exon 7 (Supplementary Figure S7), although in
each case the magnitude of change was small. In a further
unbiased attempt to identify PTBP3 functions in splicing
and translation regulation in K562 cells, we analysed the
global consequences of PTBP3 knockdownusing splice sen-
sitive HJAYmicroarrays (6) and the polyosome:monosome
ratio of cytoplasmic mRNAs. However, we found no sig-
nificant changes in transcript levels, alternative splicing or
polysome loading (PW and CWJS, unpublished observa-
tion). PTBP3 was reported to influence NMD in HEK293
cells (21). However, we observed no changes in transcript
levels that would be consistent with such a role in K562
cells. Our data therefore indicates that PTBP3 does not play
an important non-redundant role in K562 cells, despite the
similar levels of PTBP1 and PTBP3 mRNAs and the read-
ily detectable PTBP3 expression (Figure 1, (19)). Consistent
with this, western blots with reference recombinant PTBP1
and PTBP3 protein, indicated that PTBP1 is present at lev-
els ∼20-fold higher than PTBP3 in K562 cells (Figure 5C)).
A recently published ‘draft map’ of the human proteome
indicated that PTBP3 is most highly expressed in B-cells
and T-cells (37), with relatively lower levels of PTBP1 and
2 in B-cells. In agreement with this, we observed higher
levels of PTBP3 relative to PTBP1 in B-cells (Figure 5D).
Moreover, the high levels of the full length AUG1 PTBP3
isoform (Figure 5D), indicate relaxation of the PTBP1 re-
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pression of full-length PTBP3 isoform expression. This sug-
gests that PTBP3 plays important non-redundant roles in
B-cells. We are currently in the process of generating mice
in which PTBP3 can be conditionally ablated in lymphoid
cells in vivo. Our data on the diversity of PTBP3 mRNA
isoforms and the ways in which they can initiate translation
has been informative in developing a strategy for design of
a PTBP3 knockout that should lack the ability to gener-
ate any functional proteins. The phenotypes of these mice
should indicate the cell-types and developmental stages at
which PTBP3 plays key non-redundant roles. We will then
be better placed to examine in detail the functional differ-
ences in the isoforms of PTBP3.
PTBP1 and 2 both promote skipping of PTBP3 exon
2 (Figure 1), but unlike the regulated splicing events in
PTBP1 (22) and PTBP2 (15–17), this splicing event does not
downregulate PTBP3 mRNA levels (Supplementary Fig-
ure S3). Translation initiation by leaky scanning and/or
reinitiation is expected to be less efficient than scanning
to the cap-proximal AUG (31). Nevertheless, it is notable
that PTBP1/PTBP2 knockdown led to the appearance of
the full length AUG1 PTBP3 isoform without a major in-
crease in the quantity of PTBP3 protein (Figure 1). This
suggests that other post-transcriptional mechanisms might
operate to limit the expression of PTBP3 outside the ap-
propriate cell type. These mechanisms might include the in-
fluence of micro-RNAs, the suboptimal codon content of
PTBP3 (mammalian expression constructs used here were
codon optimized, as had previously been carried out for
PTBP2 (20)), and also its GC-rich 5′ UTR, which con-
tains predicted G-quadruplex structures which can render
translation particularly sensitive to the availability of he-
licases (38). Future investigations will focus on both the
physiological roles of PTBP3 as well as the various ways
in which its expression is regulated. Finally, although the
PTBP1/PTBP2 regulated splicing of PTBP3 does not act as
an ON/OFF switch, it will be interesting to investigate the
extent to which this event is a target of other splicing regu-
lators in lymphoid cell splicing regulatory networks (1,39).
We anticipate that a change in the balance of PTBP3 ver-
sus PTBP1 activity will play an important role in lymphoid
cell physiology perhaps analogous to the interplay between
hnRNPL and hnRNPLL during T-cell activation (40–43).
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